Molecular Imaging Platform provides researchers with access to state-of-the-art ZEISS imaging systems
ZEISS is proud to announce its partnership with the Molecular Imaging Platform, the core research imaging facility at the Research Institute of the McGill University Health Centre (RI-MUHC). The Molecular Imaging Platform provides researchers with access to state-of-the-art ZEISS imaging systems customized for various types of applications. The platform’s recent purchases include a ZEISS ELYRA PS.1 superresolution microscopy combi-system with ZEISS LSM 880; two multiphoton ZEISS LSM microscopes; and a spinning disk confocal microscope, ZEISS Cell Observer SD. Purchased with funds from the Canada Foundation for Innovation and the ministère de Santé et des Services sociaux du Québec, these instruments will allow the Molecular Imaging Platform to offer its users a broad range of high-end imaging modalities for many years to come.
The ELYRA superresolution microscope is configured with photo-activated localization microscopy (PALM), structured illumination microscopy (SIM) and laser scanning spectral confocal (LSM) modalities, which will allow visualization of structures down to 10nm. Cell Observer SD is capable of high-speed optical sectioning. Ideal for examination of subcellular dynamics, it is equipped with a Yokogawa CSU-X1 and two EMCCD cameras for high-sensitivity dual-channel imaging.
Further capabilities of this system are Total Internal Reflection Fluorescence (TIRF) microscopy and Fluorescence Recovery After Bleaching (FRAP) with live cell specimens. Additional ZEISS LSM multiphoton microscopy systems allow for deep tissue animal imaging with both MPX and OPO capabilities for extended IR wavelength and dual-beam excitation for multimodal imaging, combined with a high-sensitivity spectral confocal scanner with a 32 GAASP detector that allows separation of up to 10 channels in one scan.
“We are delighted to have these state-of-the-art instruments housed under one roof at our new Glen site facilities, where they will serve the needs of many RI-MUHC investigators. The microscopes are already in great demand and we are starting to see important biological questions addressed, obtaining exciting results in ways that were not possible in the past,” said Dr. Stéphane Laporte, Director of the Molecular Imaging Platform and Associate Leader of the Experimental Therapeutics and Metabolism Program at the RI-MUHC.
Abdel Barraj, General Manager for ZEISS Canada commented, “We value our relationship and partnership with the community at the RI-MUHC and look forward to supporting their research with the best imaging technologies from ZEISS now available at the Molecular Imaging Platform. The equipment will allow the facility to provide superresolution microscopy for its users and access to the first ZEISS LSM 880 spectral confocal installed in Canada. The capabilities at the facility are broad, allowing users to image live cell dynamics with Cell Observer SD and to image deep tissue structures with the only ZEISS LSM multiphoton systems in Canada with OPO and MPX functionality.”
The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and hospital research centre. Located in Montreal, Quebec, the Institute is the research arm of the McGill University Health Centre affiliated with the Faculty of Medicine at McGill University. The Research Institute offers a dynamic multidisciplinary research environment that fosters collaboration and leverages discovery aimed at improving the health of individual patients across their lifespan.
The post ZEISS Announces Partnership with Molecular Imaging Platform at McGill University Health Centre appeared first on Microscopy News Blog.